Ghrelin Receptor Antagonists
Overview
Ghrelin receptor antagonists are a class of peptides and peptidomimetics designed to block the growth hormone secretagogue receptor (GHSR), also known as the ghrelin receptor. Ghrelin is a 28-amino acid orexigenic peptide that stimulates appetite and promotes food intake. By antagonizing GHSR, these agents aim to reduce hunger signals and promote satiety, with therapeutic potential in obesity and metabolic disorders. The class includes both peptide-based molecules and small-molecule antagonists targeting the same receptor.
Key Research Findings
Early-phase clinical trials have explored various ghrelin receptor antagonists for obesity and cachexia, though no agent has achieved regulatory approval to date. Preclinical models have demonstrated reduced food intake and body weight in rodents treated with peptide antagonists. Clinical development has been limited by challenges in demonstrating sustained weight loss and acceptable safety profiles.
Subcutaneous injection, Oral
In Clinical Trials
Interested in Ghrelin Receptor Antagonists?
Find a verified provider experienced with Ghrelin Receptor Antagonists protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Ghrelin Receptor Antagonists ProviderRelated Peptides
Octreotide (Sandostatin)
FDA ApprovedA synthetic octapeptide analog of somatostatin with a substantially longer half-life (90 minutes IV, 6 hours subcutaneous vs. 2 minutes for native somatostatin). Octreotide binds somatostatin receptors (primarily SSTR2 and SSTR5) to inhibit the secretion of GH, glucagon, insulin, gastrin, secretin, VIP, and other GI hormones. It reduces splanchnic blood flow, GI motility, and exocrine pancreatic secretion.
Lanreotide (Somatuline Depot)
FDA ApprovedA synthetic octapeptide analog of somatostatin with high affinity for SSTR2 and moderate affinity for SSTR5 receptors. Lanreotide is formulated as a supersaturated solution that forms a drug depot at the injection site, providing sustained release over 4 weeks. It inhibits GH secretion, GI hormone release, and has direct antiproliferative effects on neuroendocrine tumor cells through cell cycle arrest and apoptosis induction.
Pasireotide (Signifor)
FDA ApprovedA multireceptor-targeted somatostatin analog with high binding affinity for SSTR1, SSTR2, SSTR3, and SSTR5, particularly notable for its 40-fold greater affinity for SSTR5 compared to octreotide. This receptor profile makes pasireotide uniquely effective in Cushing's disease, where corticotroph adenomas predominantly express SSTR5. Pasireotide suppresses ACTH secretion from pituitary corticotroph tumors, reducing cortisol production.
Plecanatide (Trulance)
FDA ApprovedA synthetic 16-amino acid peptide structurally related to uroguanylin, an endogenous intestinal peptide that regulates fluid and electrolyte homeostasis in the GI tract. Plecanatide activates guanylate cyclase-C (GC-C) receptors on intestinal epithelial cells in a pH-dependent manner, preferentially in the proximal small intestine where pH is slightly acidic. GC-C activation increases intracellular and extracellular cGMP, stimulating chloride and bicarbonate secretion while reducing visceral pain signaling.